Our liver experts are well knowned authorities in their sub specialisms and contribute regularly to national and international publications. Newcastle’s author input is highlighted in bold.
Autoimmune liver disease
Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis
Taubert R, Engel B, Diestelhorst J, Hupa-Breier K, Behrendt P, Baerlecken NT, Sühs KW, Janik MK, Zachou K, Sebode M, Schramm C, Londoño MC, Habes S, UK-AIH Consortium; Oo YH, Lalanne C, Pape S, Schubert M, Hust M, Dübel S, Thevis M, Jonigk D, Beimdiek J, Buettner FFR, Drenth JPH, Muratori L, Adams DH, Dyson JK, Renand A, Graupera I, Lohse AW, Dalekos GN, Milkiewicz P, Stangel M, Maasoumy B, Witte T, Wedemeyer H, Manns MP, Jaeckel E, Hepatology 75.1 (2022): 13-27.
UDCA Response Criteria in Primary Biliary Cholangitis and Its Relationship to Disease Activity.
Jones DEJ; Wetten A; Barron-Millar B; Ogle L; Mells G; Flack S; Badrock J; Sandford R; Kirby J; Palmer J; Brotherston S; Wong K; Jopson L; Brain J; Smith GR; Rushton S; Hegade VS; Jones R; Rushbrook S; Thorburn D; Ryder SD; Hirschfield G; UK-PBC Research Consortium ; Dyson JK Accepted by EBio Medicine April 2022. DOI: 10.1016/j.ebiom.2022.104068
Patient priorities in autoimmune hepatitis: the need for better treatments, more education and challenging stigma.
Lloyd C, Leighton J, Wong LL, Goulding A, Brownlee A, Gray P, Culver E, Halliday N, Thorburn D, Heneghan MA, Jones DEJ, Exley C and Dyson JK. Accepted for publication by Digestive Diseases and Sciences April 2022. DOI: 10.1007/s10620-022-07525-5
The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis
Barron-Millar B, Ogle L, Mells G, Flack S, Badrock J, Sandford R, Kirby J, Palmer J, Jopson L, Brain J, Smith GR, Rushton S, Hegade VS, Jones R, Rushbrook S, Thorburn D, Ryder S, Hirschfield G, UK-PBC Research Consortium, Dyson JK, Jones DEJ Hepatology 74.6 (2021): 3269-3283.
Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough?
Wetten A, Jones DEJ and Dyson JK Expert Opinion on Pharmacotherapy. 2021 Oct;22(15):1949-1953. DOI: 10.1080/14656566.2021.1940135
Review article: experimental therapies in autoimmune hepatitis.
Halliday N, Dyson JK, Thorburn D, Lohse AW, Heneghan MA. Aliment Pharmacol Ther. 2020 Oct;52(7):1134-1149
Managing cognitive symptoms and fatigue in cholestatic liver disease.
Phaw NA, Leighton J, Dyson JK, Jones DEJ. Expert Rev Gastroenterol Hepatol. 2020 Nov 11:1-7. doi: 10.1080/17474124.2021.1844565.
Understanding of fatigue in Primary Biliary Cholangitis. Digestive Diseases and Sciences
Phaw NA, Dyson JK, Mells G, Jones DEJ. Dig Dis Sci. 2021 Jul;66(7):2380-2386.
doi: 10.1007/s10620-020-06502-0. Epub 2020 Aug 26.
Patient ownership of Primary Biliary Cholangitis long term management.
Leighton J, Thain C, Thain R, Dyson JK, Jones DEJ. Frontline Gastroenterology, 2020, flgastro-2019-101324; DOI: 10.1136/flgastro-2019-101324
UDCA Prophylaxis for Post-Transplant PBC Recurrence Prevention: Time to Change Practice
Dyson JK, Jones DEJ.. J Hepatol. 2020 Jun 20;S0168-8278(20)30286-5.
Emerging drugs for the treatment of primary biliary cholangitis.
Phaw NA, Dyson JK, Jones DEJ. Expert Opin Emerg Drugs. 2020 Jun;25(2):101-112.
Unanswered clinical and research questions in auto-immune hepatitis: conclusions of the International Autoimmune Hepatitis Group Research Workshop.
Dyson JK, De Martin E, Dalekos GN, Drenth JPH, Herkel J, Hubscher SG, Kelly D, Lenzi M, Milkiewicz P, Oo YH, Heneghan MA, Lohse AW, on behalf of the IAIHG Consortium. Aliment Pharmacol Ther. 2019 Mar;49(5):528-536.
British Society of Gastroenterology and UK-PSC Consortium Guidelines for the diagnosis and management of primary sclerosing cholangitis
Chapman MH, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, Collier J, Dyson JK, Jones DEJ, Patanwala I, Thain C, Walmsley M and Pereira SP.. Gut. 2019 Aug;68(8):1356-1378.
Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom.
Dyson JK, Wong LL, Bigirumurame T, Hirschfield GM, Kendrick S, Oo YH, Lohse AW, Heneghan MA, Jones DEJ; UK-AIH Consortium. Aliment Pharmacol Ther. 2018 Nov;48(9):951-960.
Primary Sclerosing Cholangitis – Seminar.
Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Lancet. 2018 Jun 23;391(10139):2547-2559.
The Impact of Autoimmune Hepatitis and its Treatment on Health Utility.
Wong LL, Fisher H, Stocken DD, Rice S, Khanna A, Heneghan MA, Oo YH, Kendrick S, Dyson JK*, Jones DEJ*1 and UK-AIH Consortium (* joint last authors). Hepatology. 2018 Oct;68(4):1487-1497.
Changes in NK cells and exhausted, memory regulatory T cells with corticosteroid therapy in acute autoimmune hepatitis.
Jeffrey HC, Braitch MK, Bagnall C, Hodson J, Jeffery LE, Wawman RE, Wong LL, Birtwistle, Bartlett H, Lohse AW, Hirschfield GM, Dyson JK, Jones DEJ, Hubscher SG, Klenerman P, Adams SH, Oo YH, on behalf of the UK-AIH consortium. Hepatol Commun. 2018 Feb 26;2(4):421-436.
Primary Biliary Cholangitis Treatment and Management Guidelines.
Hirschfield GM, Dyson JK, Alexander GJ, Chapman M, Collier J, Hubscher S, Patanwala I, Pereira S, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G and Jones DEJ. British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis Treatment and Management Guidelines. Gut. 2018 Sep;67(9):1568-1594.
Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis
Dyson JK, Blain A, Foster Shirley MD, Hudson M, Rushton S, Jeffreys Jones DE. JHEP Rep. 2020 Nov 4;3(1):100202. doi: 10.1016/j.jhepr.2020.100202
Viral hepatitis
Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
Askar S, Jelley R, McQue K, Allsop C, McCullough F, Miller C, Taha Y, Masson S, McPherson S.J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13707.
Viral hepatitis in 2021: The challenges remaining and how we should tackle them.
Dunn R, Wetten A, McPherson S, Donnelly MC.World J Gastroenterol. 2022 Jan 7;28(1):76-95. doi: 10.3748/wjg.v28.i1.76.PMID: 35125820
Progress towards micro-elimination of hepatitis C in the custodial setting.
Gallacher J, McPherson S. J Viral Hepat. 2021 Feb;28(2):300-301.
Digest This! Hepatitis E virus
Ribavirin for hepatitis E infection after organ transplantation: a large European retrospective multicenter study:
Kamar N, Abravanel F, Behrendt P, Hofmann J, Pageaux GP, Barbet C, Moal V, Couzi L, Horvatits T, De Man RA, Cassuto E, Elsharkaway AM, Riezebos-Brilman A, Scemla A, Hillaire S, Donnelly MC et al; Hepatitis E Virus Ribavirin Study Group. Clin Infec Dis 2020; 22: 1204 – 1211
Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection:
Avellon A, Ala A, Diaz A, Domingo D, Gonzalez R, Hidalgo L, Kooner P, Loganathan S, Martin D, McPherson S et al. J Med Virol 2020 doi: 10.1002/jmv.25862.
High rates of hepatitis C reinfection following antiviral treatment in the North East England Prisons:
Bhandari R, Moery S, Hamoodi A, Thompson C, Jones D, Hewett M, Hunter E, Taha Y, McPherson S. J Viral Hepat 2020; 27: 449 – 452
Fatty liver disease
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group.
McPherson S, Armstrong MJ, Cobbold JF, Corless L, Anstee QM, Aspinall RJ, Barclay ST, Brennan PN, Cacciottolo TM, Goldin RD, Hallsworth K, Hebditch V, Jack K, Jarvis H, Johnson J, Li W, Mansour D, McCallum M, Mukhopadhya A, Parker R, Ross V, Rowe IA, Srivastava A, Thiagarajan P, Thompson AI, Tomlinson J, Tsochatzis EA, Yeoman A, Alazawi W.Lancet Gastroenterol Hepatol. 2022 Apr 28:S2468-1253(22)00061-9. doi: 10.1016/S2468-1253(22)00061-9. Online ahead of print.
Current therapies and new developments in NASH.
Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S.Gut. 2022 Jun 16:gutjnl-2021-326874. doi: 10.1136/gutjnl-2021-326874.
Impact of non-invasive biomarkers on hepatology practice: Past, present and future.
Anstee QM, Castera L, Loomba R.J Hepatol. 2022 Jun;76(6):1362-1378. doi: 10.1016/j.jhep.2022.03.026
Predicting Liver-Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests.
Johnson AL, Hayward KL, Patel P, Horsfall LU, Cheah AEZ, Irvine KM, Russell AW, Stuart KA, Williams S, Hartel G, Valery PC, Powell EE. Hepatol Commun. 2022 Apr;6(4):728-739. doi: 10.1002/hep4.1852. Epub 2021 Nov 15.
Depressive symptoms in non-alcoholic fatty liver disease are identified by perturbed lipid and lipoprotein metabolism.
Radford-Smith DE, Patel PJ, Irvine KM, Russell A, Siskind D, Anthony DC, Powell EE, Probert F.PLoS One. 2022 Jan 6;17(1):e0261555. doi: 10.1371/journal.pone.0261555. eCollection 2022.PMID: 34990473
Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety.
Hayward KL, Valery PC, Patel PJ, Li C, Horsfall LU, Wright PL, Tallis CJ, Stuart KA, David M, Irvine KM, Cottrell N, Martin JH, Powell EE.Pharmaceuticals (Basel). 2021 Nov 23;14(12):1207. doi: 10.3390/ph14121207.PMID: 34959611
Embedding assessment of liver fibrosis into routine diabetic review in primary care.
Mansour D, Grapes A, Herscovitz M, Cassidy P, Vernazza J, Broad A, Anstee QM, McPherson S.JHEP Rep. 2021 Apr 22;3(4):100293. doi: 10.1016/j.jhepr.2021.100293. eCollection 2021 Aug.PMID: 34179738
Feasibility of a very low calorie diet to achieve a sustainable 10% weight loss in patients with nonalcoholic fatty liver disease.
Scragg J, Avery L, Cassidy S, Taylor G, Haigh L, Boyle M, Trenell MI, Anstee QM, McPherson S, Hallsworth K.Clin Transl Gastroenterol. 2020 Sep;11(9):e00231.
Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review.
Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand MH.Liver Int. 2021 Feb;41(2):261-270
Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis:
Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN. Gastroenterology 2020; 158: 1611 – 1625
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study:
Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik FB, Darteil R, Liebe R, Magnanensi J, Hajji Y, Brozek J, Roudot A, Staels B, Hum DW, Megnien SJ, Hosmane S, Dam N, Chaumat P, Hanf R, Anstee QM, Sanyal AJ. Lancet Gastroenterol Hepatol 2020 doi: 10.1016/S2468-1253(20)30252-1
Presence of serum antinuclear antibodies does not impact long-term outcomes in nonalcoholic fatty liver disease:
Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Fracanzani AL, Rosso C, Blanco MJG, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Valenti L, Anstee QM, Bugianesi E. Am J Gastroenterol 2020; 115: 1289 – 1292
Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease.
Neilson LJ, MacDougall L, Lee PS, Hardy T, Beaton D, Chandrapalan S, Ebraheem A, Hussien M, Galbraith S, Looi S, Oxenburgh S, Phaw N, Taylor W, Haigh L, Hallsworth K, Mansour D, Dyson JK, Masson S, Anstee QM, McPherson S. Frontline Gastroenterol. Accepted for publication
The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study.
Connoley D, Patel PJ, Hogan B, Tanwar S, Rhodes F, Parkes J, Burt A, Watkins J, Sievert W, Rosenberg W.BMC Gastroenterol. 2021 Jun 28;21(1):268. doi: 10.1186/s12876-021-01795-5.
Liver Transplantation
SARS-CoV-2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID-19 Vaccination.
Moon AM, Webb GJ, García-Juárez I, Kulkarni AV, Adali G, Wong DK, Lusina B, Dalekos GN, Masson S, Shore BM, Barnes E, Barritt AS 4th, Marjot T.Hepatol Commun. 2022 Apr;6(4):889-897. doi: 10.1002/hep4.1853. Epub 2021 Nov 9.
Resuming liver transplantation amid the COVID-19 pandemic.
Thorburn D, Taylor R, Whitney J, Adair A, Attia M, Gibbs P, Grammatikopoulos T, Isaac JR, Masson S, Marshall A, Mirza DF, Prachalias A, Watson S, Manas DM, Forsythe J. Lancet Gastroenterol Hepatol. 2021 Jan;6(1):12-13
Pregnancy outcomes in women with liver transplants: systematic review and meta-analysis:
Marson EJ, Kamarajah SK, Dyson JK, White SA. HPB 2020; 22: 1102 – 1111
Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.
Vaziri A, Gimson A, Agarwal K, Aldersley M, Bathgate A, MacDonald D, McPherson S, Mutimer D, Gelson W.J Viral Hepat. 2019 Feb;26(2):231-235. doi: 10.1111/jvh.13022. Epub 2018 Nov 14.PMID: 30339294
Liver transplantation for alcohol-related liver disease in the UK: revised UK Liver Advisory Group recommendations for referral.
Masson S, Aldersley H, Leithead JA, Day E, Langford A, Healy P, O’Grady J, Thorburn D, Parker C, Shepherd L, Arndtz K, Webb K, Holt A.Lancet Gastroenterol Hepatol. 2021 Nov;6(11):947-955. doi: 10.1016/S2468-1253(21)00195-3.PMID: 34626562
Twitter debate: controversies in liver transplantation.
Tavabie OD, Srivastava A, Dillon A, Mirza D, Masson S, Smith PJ.Frontline Gastroenterol. 2021 Jun 21;13(3):262-265. doi: 10.1136/flgastro-2021-101916. eCollection 2022.PMID: 35493621
Hepatocellular carcinoma and Cholangiocarcinoma
COVID-19 and liver cancer: lost patients and larger tumours. BMJ open gastroenterology.
Geh D, Watson R, Sen G, French JJ, Hammond J, Turner P, Hoare T, Anderson K, McNeil M, McPherson S, Masson S, Dyson J, Donnelly M, MacDougal L, Patel P, Hudson M, Anstee QM, White S, Robinson S, Pandanaboyana S, Walker L, McCain M, Bury Y, Raman S, Burt A, Parkinson D, Haugk B, Darne A, Wadd N, Asghar S, Mariappan L, Margetts J, Stenberg B, Scott J, Littler P, Manas DM and Reeves HL. 2022 Apr 1;9(1):e000794.
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, D’Ambrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele L, Vespasiani-Gentilucci U, Anstee QM, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, Soardo G, Reeves H, Prati D, Romeo S, Valenti L.J Hepatol. 2021 Apr;74(4):775-782. doi: 10.1016/j.jhep.2020.11.024. Epub 2020 Nov 25.PMID: 33248170
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM.J Hepatol. 2021 Oct;75(4):865-878. doi: 10.1016/j.jhep.2021.04.049. Epub 2021 May 13.PMID: 33992698
NAFLD-Associated HCC: Progress and Opportunities.
Geh D, Anstee QM, Reeves HL.J Hepatocell Carcinoma. 2021 Apr 8;8:223-239. doi: 10.2147/JHC.S272213. eCollection 2021.PMID: 33854987
Combined hepatocellular-cholangiocarcinoma – More questions than answers.
Hubner RA, Reeves HL, Edeline J.Liver Int. 2021 Jun;41(6):1186-1188. doi: 10.1111/liv.14894.PMID: 34002474
Hepatocellular carcinoma in non-alcoholic fatty liver disease – a review of an emerging challenge facing clinicians.
Geh D, Manas DM, Reeves HL.Hepatobiliary Surg Nutr. 2021 Jan;10(1):59-75
Development of a novel inflammation-based index for hepatocellular carcinoma:
Chan SL, Wong LL, Chan KA, Chow C, Tong JH, Yip TC, Wong GL, Chong CC, Liu PH, Chu CM, Wong VW, To KF, Reeves HL, Chan AW. Liver Cancer 2020; 9: 167 – 181
Characterisation of the serum metabolic signature of cholangiocarcinoma in a United Kingdom cohort:
Alsaleh M, Leftley Z, Barbera TA, Koomson LK, Zabron A, Crossey MMR, Reeves HL et al. J Clin Exp Hepatol 2020; 10: 17 – 29
From NASH to HCC: current concepts and future challenges.
Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M.Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. doi: 10.1038/s41575-019-0145-7.PMID: 31028350
Alcohol Related Liver Disease
Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors.
Schwantes-An TH, Darlay R, Mathurin P, Masson S, Liangpunsakul S, Mueller S, Aithal GP, Eyer F, Gleeson D, Thompson A, Muellhaupt B, Stickel F, Soyka M, Goldman D, Liang T, Lumeng L, Pirmohamed M, Nalpas B, Jacquet JM, Moirand R, Nahon P, Naveau S, Perney P, Botwin G, Haber PS, Seitz HK, Day CP, Foroud TM, Daly AK, Cordell HJ, Whitfield JB, Morgan TR, Seth D; GenomALC Consortium.Hepatology. 2021 May;73(5):1920-1931. doi: 10.1002/hep.31535.
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
Whitfield JB, Schwantes-An TH, Darlay R, Aithal GP, Atkinson SR, Bataller R, Botwin G, Chalasani NP, Cordell HJ, Daly AK, Day CP, Eyer F, Foroud T, Gleeson D, Goldman D, Haber PS, Jacquet JM, Liang T, Liangpunsakul S, Masson S, Mathurin P, Moirand R, McQuillin A, Moreno C, Morgan MY, Mueller S, Müllhaupt B, Nagy LE, Nahon P, Nalpas B, Naveau S, Perney P, Pirmohamed M, Seitz HK, Soyka M, Stickel F, Thompson A, Thursz MR, Trépo E, Morgan TR, Seth D; GenomALC Consortium.J Hepatol. 2022 Feb;76(2):275-282. doi: 10.1016/j.jhep.2021.10.005. Epub 2021 Oct 14.PMID: 34656649
The diagnostic and prognostic significance of liver histology in alcoholic hepatitis.
Forrest E, Petts G, Austin A, Lloyd K, Wright M, Vergis N, Atkinson S, Masson S, Patch D, Quaglia A, Thursz M, Goldin R.Aliment Pharmacol Ther. 2021 Feb;53(3):426-431. doi: 10.1111/apt.16157. Epub 2020 Dec 16.PMID: 33326633
The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study.
Connoley D, Patel PJ, Hogan B, Tanwar S, Rhodes F, Parkes J, Burt A, Watkins J, Sievert W, Rosenberg W.BMC Gastroenterol. 2021 Jun 28;21(1):268. doi: 10.1186/s12876-021-01795-5
Miscellaneous
Obesity, diabetes, coffee, tea and cannabis use alter risk for alcohol-related cirrhosis in 2 large cohorts of high-risk drinkers.
Whitfield JB, Masson S, Liangpunsakul S, Mueller S, Aithal GP, Eyer F, Gleeson D, Thompson A, Stickel F, Soyka M, Muellhaupt B, Daly AK, Cordell HJ, Foroud T, Lumeng L, Pirmohamed M, Nalpas B, Jacquet JM, Moirand R, Nahon P, Naveau S, Perney P, Haber PS, Seitz HK, Day CP, Mathurin P, Morgan TR, Seth D; GenomALC Consortium. Am J Gastroenterol. 2021 Jan 1;116(1):106-115
Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma:
Stuart L, Lambourne B, Turner P, Jones DEJ, Plummer R, Cresti N, Dyson JK. Hepatology 2020; 71: 2164 – 2166
Paediatric to adult liver transition services: the state of play in the UK.
Joshi D, Dyson J, Hudson M, Levitsky J, Heldman M, Samyn, M. Clin Med. 2019; 19:425-426.
Lancet Commission on Liver Disease
Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK.
Williams R, Alexander G, Aspinall R, Batterham R, Bhala N, Bosanquet N, Severi K, Burton A, Burton R, Cramp ME, Day N, Dhawan A, Dillon J, Drummond C, Dyson J, Ferguson J, Foster GR, Gilmore I, Greenberg J, Henn C, Hudson M, Jarvis H, Kelly D, Mann J, McDougall N, McKee M, Moriarty K, Morling J, Newsome P, O’Grady J, Rolfe L, Rice P, Rutter H, Sheron N, Thorburn D, Verne J, Vohra J, Wass J, Yeoman A. Lancet. 2018 Dec 1;392(10162):2398-2412.
Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK.
Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, de Lusignan S, Day N, Dhawan A, Dillon J, Drummond C, Dyson J, Foster G, Gilmore I, Hudson M, Kelly D, Langford A, McDougall N, Meier P, Moriarty K, Newsome P, O’Grady J, Pryke R, Rolfe L, Rice P, Rutter H, Sheron N, Taylor A, Thompson J, Thorburn D, Verne J, Wass J, Yeoman A. Lancet. 2018 Mar 17;391(10125):1097-1107.
